MabThera/Rituxan

Ocrevus helps Roche shrug off biosimilars in 2018

The drugmaker reported sales up 7% to 56.8bn Swiss francs ($57.1bn) for 2018, with a 7% decline in Europe caused mainly by falls for MabThera/Rituxan (rituximab) and breast ... Roche said it thinks the same pattern will be evident this year, however,

Imbruvica and Gazyvo approved in first non-chemo CLL use

The approval is also good news for Roche and its drug Gazyvo (obinutuzumab) which the company is trying to prove as superior next-generation version of MabThera/Rituxan (rituximab) which is

CHMP backs Sanofi’s all-oral sleeping sickness drug

remission with minimal residual disease greater than or equal to 0.1%, and also backed Roche’s MabThera (rituximab) for adults with severe, active granulomatosis with polyangiitis and microscopic polyangiitis in

Roche and AbbVie prepare to move Venclexta into first-line CLL

Gazyva is a follow-up to Roche’s big-selling Rituxan/MabThera (rituximab) anti-CD20 drug – a mainstay of CLL therapy given alongside chemotherapy – and was approved alongside chlorambucil for ... Venclexta is a key growth product for both companies

Roche’s new flu pill Xofluza approved in US

Roche is in need of a new set of innovative products, as its older generation of blockbusters, Avastin, Herceptin and MabThera/Rituxan come under competition from biosimilars.

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]